

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



BrainAurora Medical Technology Limited

脑动极光医疗科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6681)

RESIGNATION OF EXECUTIVE DIRECTOR, CHIEF EXECUTIVE OFFICER AND CHIEF RESEARCH OFFICER

This announcement is made by the board (the “**Board**”) of directors (the “**Director(s)**”) of BrainAurora Medical Technology Limited 脑动极光医疗科技有限公司 (the “**Company**”, together with its subsidiaries, the “**Group**”) in accordance with Rule 13.51(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

The Company hereby announces that Dr. Wang Xiaoyi (“**Dr. Wang**”) has submitted his resignation as executive Director, chief executive officer (“**CEO**”) and chief research officer (“**CRO**”) of the Group, with effect from June 19, 2025. The reasons for his resignation are as follows:

“My resignation stems from health issues caused by worsening depression. Although I have always been passionate about the Company’s business and honored to participate in R&D at the Company, a top domestic enterprise, I have long endured enormous pressure at work, especially during the Company’s preparation for listing, when the pressure peaked and led to severe depression. After the listing, my condition continued to deteriorate, with persistent headaches, insomnia, low mood, severe anxiety, reaching an unbearable level. After in-depth communication with the medical team and careful consideration, I confirm that it is necessary to suspend all work for the time being and focus on treatment and recovery. This decision is made both for my health needs and to ensure the stability of corporate governance. I believe that when my health allows and the Company needs me in the future, I will definitely return to the team to contribute again. I promise to fully cooperate in the work handover and the procedures for changing the legal representative, and will sign all required documents to ensure a smooth transition of duties.

Looking back on the journey with the Company, I am deeply grateful. The proudest moment for me was when, with the trust of the Board and shareholders and the colleagues’ collaboration, we jointly achieved the historic milestone of listing on the Hong Kong Stock Exchange. The day-and-night efforts from preparation to the listing ceremony exemplified the Company’s strategic resilience, team tenacity, and industry influence – this entire journey remain the brightest chapter in my career. This achievement embodies the wisdom and hard work of every colleague and confirms the Company’s excellent cultural DNA and development vision.

Here, I would like to extend my sincerest gratitude to the Board for granting me the precious opportunity to lead the Company and for their unwavering support; I also sincerely thank the management partners for their sincere cooperation and all employees for their full dedication. The Company’s innovative environment and inclusive values have allowed me to pour my passion here, and this camaraderie will always be engraved in my heart.

Finally, I earnestly request the Board to understand this decision and approve my resignation. I sincerely wish the Company to scale new heights and enjoy everlasting prosperity under the leadership of the new management team! ”

Dr. Wang has confirmed that there is no disagreement between himself and the Board, and there are no issues in respect of his resignation that need to be brought to the attention of the Company’s shareholders.

The Board further announces that, with immediate effect, Mr. Cai Longjun (蔡龍軍), chief technology officer and chief operating officer of the Group, is authorized to act as CEO and CRO, responsible for the daily affairs of the Company and serving as the legal representative, general manager, manager, and director of the Group’s subsidiaries originally held by Dr. Wang.

The Board would like to take this opportunity to express its gratitude to Dr. Wang for his valuable contributions to the Company during his tenure.

By order of the Board
BrainAurora Medical Technology Limited
脑动极光医疗科技有限公司
Tan Zheng
Chairman and Executive Director

Hong Kong, June 19, 2025

As of the date of this announcement, the Board comprises: (i) Mr. Tan Zheng as executive Director; (ii) Mr. Li Sirui, Ms. Li Mingqiu and Mr. Deng Feng as non-executive Directors; and (iii) Mr. Lam Yiu Por, Dr. Duan Tao and Mr. Li Yuezhong as independent non-executive Directors.